IRF4 and diffuse large B-cell lymphoma: In xenograft models of DLBCL, lenalidomide demonstrated major clinical activity on ABC-subtype, in which there was downregulation of B-cell receptor-dependent NF-kB through an inhibition of the transcription factor interferon regulatory factor 4 (IRF4) and cerebron20.